Featured Articles

  1. Defining Meaningful Anti-Inflammatory Response: What Early Human Data Tells Us 9/22/2026

    Controlled immune challenges link drug exposure to biological effects, helping refine dose selection, test mechanisms and support better decisions before patient trials.

  2. 5 Questions That Reveal Whether A Drug Programme Is Built To Succeed 9/22/2026

    Explore how Question-Based Drug Development helps teams build knowledge, reduce avoidable surprises and make stronger scientific and investment decisions.

  3. Proving CNS Target Engagement With Neuroimaging In Early Clinical Drug Development 8/27/2026

    The key question is not whether a scan changes, but what link in the dose-to-effect chain it resolves. Combining PET, MRI, PK/PD, and functional measures reduces uncertainty.

  4. 7 Practical Implications Of ICH E6(R3) For Early-Phase Trial Design 8/10/2026

    A risk-based quality approach can enhance participant protection, data integrity, and development success through focused oversight, strong governance, and clear documentation.

  5. What Controlled Immune Challenges Reveal Before Patient Studies Begin 7/30/2026

    Controlled immune challenges can reveal target engagement and pharmacology before efficacy is measurable, supporting earlier and more informed development decisions.

  6. Making Early Decisions In Psychiatric Drug Development 7/30/2026

    Quantitative PD measures provide objective evidence of target engagement, support dose selection, strengthen early go/no-go decisions, and help reduce development risk in psychiatric

  7. How NeuroKit® Helps Avoid False Negatives in Early CNS Development 7/30/2026

    Detecting subtle CNS effects early can reduce false negatives. Sensitive assessments strengthen confidence in pharmacodynamic signals and dose selection.

     

  8. EU Clinical Trial Regulation Timelines: Shorter Than Many Expect 7/30/2026

    The EU CTR rewards early planning. Strong documentation, regulatory readiness, and aligned partners can help accelerate approvals and reduce delays.

  9. Building Recruitment Into Early-Phase Trial Design 7/30/2026

    Successful recruitment starts with smart study design. Early recruitment insight improves feasibility, supports realistic timelines, and reduces enrollment risk.

  10. Balancing Patient Convenience And Signal Integrity In CNS Trials 7/30/2026

    Early CNS trials depend on precise data. Hybrid approaches can reduce participant burden, but critical assessments often require controlled environments to preserve signal integrity.